BRPI0408085A - composição e método para o tratamento e prevenção de infecções entéricas bacterianas - Google Patents

composição e método para o tratamento e prevenção de infecções entéricas bacterianas

Info

Publication number
BRPI0408085A
BRPI0408085A BRPI0408085-8A BRPI0408085A BRPI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A BR PI0408085 A BRPI0408085 A BR PI0408085A
Authority
BR
Brazil
Prior art keywords
composition
treatment
vaccine
prevention
antigens
Prior art date
Application number
BRPI0408085-8A
Other languages
English (en)
Inventor
Roy Michael Robins-Browne
Grant Thomas Rawlin
Gottfried Lichti
Original Assignee
Anadis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadis Ltd filed Critical Anadis Ltd
Publication of BRPI0408085A publication Critical patent/BRPI0408085A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

"COMPOSIçãO E MéTODO PARA O TRATAMENTO E PREVENçãO DE INFECçõES ENTéRICAS BACTERIANAS". A presente invenção fornece um método de tratamento ou profilaxia de doença entérica causada por bactérias Gram-negativas. O método inclui a etapa de administração de uma vacina ou de um material hiperimune desenvolvido em contato com a referida vacina a um indivíduo. A vacina compreende um ou mais antígenos da parede celular reativos de um modo característico de sorotipos do grupo O, ou reativos de um modo característico de antígenos associados a lipopolissacarídeos, e pelo menos alguns dos referidos antígenos are separados de paredes celulares bacterianas ou de fragmentos da parede. A invenção também fornece composição contendo material hiperimune, além de usos da composição e da vacina.
BRPI0408085-8A 2003-03-04 2004-03-04 composição e método para o tratamento e prevenção de infecções entéricas bacterianas BRPI0408085A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901008A AU2003901008A0 (en) 2003-03-04 2003-03-04 Composition for the treatment and prevention of bacterial infections
PCT/AU2004/000277 WO2004078209A1 (en) 2003-03-04 2004-03-04 Composition and method for the treatment and prevention of enteric bacterial infections

Publications (1)

Publication Number Publication Date
BRPI0408085A true BRPI0408085A (pt) 2006-02-14

Family

ID=31500053

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408085-8A BRPI0408085A (pt) 2003-03-04 2004-03-04 composição e método para o tratamento e prevenção de infecções entéricas bacterianas

Country Status (10)

Country Link
US (1) US8637025B2 (pt)
EP (2) EP1605975A4 (pt)
CN (2) CN1764476A (pt)
AU (1) AU2003901008A0 (pt)
BR (1) BRPI0408085A (pt)
CA (1) CA2517911C (pt)
DK (1) DK3159357T3 (pt)
ES (1) ES2903120T3 (pt)
NZ (1) NZ542088A (pt)
WO (1) WO2004078209A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417986A1 (en) 2004-11-22 2012-02-15 Anadis Ltd. Bioactive compositions
WO2008148149A1 (en) * 2007-06-05 2008-12-11 Anadis Ltd Method of treatment or inhibition of enterovirus 71 infection
EP3231816A1 (en) 2008-03-13 2017-10-18 Immuron Limited Bovine colostrum comprising anti-insulin antibodies for treating diabetes, non alcoholic fatty liver disease, hyperlipidemia or atherosclerosis.
CA2760096C (en) 2009-04-27 2018-10-30 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
US9943597B2 (en) 2010-08-17 2018-04-17 Immuron Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
TW201304786A (zh) * 2010-10-04 2013-02-01 Immuron Ltd 使用抗ｌｐｓ配體治療及預防發炎疾病的方法及組合物
KR20140043303A (ko) 2010-11-23 2014-04-09 팬더릭스 인코포레이티드 광범위한, 미확인 또는 혼합된 임상적 적용에서 치료용 조성물들 및 방법들
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
AU2012269740A1 (en) * 2011-06-17 2013-01-31 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
AU2014206799B9 (en) 2013-01-17 2018-05-10 Janssen Pharmaceuticals, Inc. MDR E. coli specific antibody
ES2940827T3 (es) 2013-04-19 2023-05-11 Immuron Ltd Procedimientos y composiciones para el tratamiento y/o la profilaxis de la enfermedad asociada a Clostridium difficile
GB201312635D0 (en) * 2013-07-15 2013-08-28 Univ Plymouth Water testing
US9017698B2 (en) * 2013-09-25 2015-04-28 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
EP3062801A1 (en) 2013-10-30 2016-09-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
CA2935532A1 (en) * 2014-02-06 2015-08-13 Arsanis Biosciences Gmbh E. coli specific antibody sequences
EP2987503A1 (en) 2014-08-22 2016-02-24 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and reagents for prevention and/or treatment of infection
US11130800B2 (en) 2016-05-20 2021-09-28 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
KR101871338B1 (ko) 2016-12-22 2018-06-26 주식회사 옵티팜 신규한 병원성 대장균 특이 박테리오파지 ec14 및 이를 포함하는 항균 조성물
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
WO2022011436A1 (en) * 2020-07-17 2022-01-20 Immuron Limited Methods of treating coronavirus infection with bovine-hyperimmune colostrum
CN112540077B (zh) * 2020-11-30 2022-12-06 邢台学院 一种原位检测种子中脂肪酸不饱和度的方法
WO2022241058A1 (en) 2021-05-12 2022-11-17 Applied Biomedical Science Institute Methods of screening and expression of disulfide-bonded binding polypeptides
EP4337689A1 (en) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
CN113603761B (zh) * 2021-08-09 2023-03-31 复旦大学附属中山医院 一种用于重症急性胰腺炎肠道功能障碍的小分子多肽
CN114521638A (zh) * 2022-01-25 2022-05-24 安徽妙奇树生物科技股份有限公司 一种具有改善便秘的水果型酵素组合物胶原果冻、果胶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3376198A (en) 1965-07-21 1968-04-02 Collins Products Inc Method of producing antibodies in milk
GB1560934A (en) * 1975-05-07 1980-02-13 Unilever Ltd Methods for the resistance of non-human mammals to gastro-intestinal disorders
US4298597A (en) * 1979-09-04 1981-11-03 University Of Saskatchewan Vaccine for diarrhea caused by E. coli
NZ201698A (en) * 1981-08-31 1985-12-13 S L Gaffin Composition of antibodies specific to endotoxins
US4971794A (en) * 1982-09-02 1990-11-20 Unilever Patent Holdings B.V. Production of antibodies using a mixture of strains of E. coli collectively expressing type I pili, CFA I pili, CFA II pili and K88 pili
ZA836349B (en) * 1982-09-02 1985-04-24 Unilever Plc Production of antibodies
US5179018A (en) 1983-10-14 1993-01-12 Centocor, Inc. Mamalian monoclonal antibodies against endotoxin of gram-negative bacteria
US5017372A (en) 1986-04-14 1991-05-21 Medicis Corporation Method of producing antibody-fortified dry whey
GB9018061D0 (en) 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
US5780028A (en) 1993-09-20 1998-07-14 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
KR20100137015A (ko) * 2002-03-21 2010-12-29 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물, 제조 및 치료 방법

Also Published As

Publication number Publication date
US20070053917A1 (en) 2007-03-08
NZ542088A (en) 2008-04-30
DK3159357T3 (da) 2022-04-04
EP1605975A1 (en) 2005-12-21
CA2517911A1 (en) 2004-09-16
US8637025B2 (en) 2014-01-28
WO2004078209A1 (en) 2004-09-16
CN1764476A (zh) 2006-04-26
EP3159357A1 (en) 2017-04-26
AU2003901008A0 (en) 2003-03-20
CN102698258A (zh) 2012-10-03
ES2903120T3 (es) 2022-03-31
CA2517911C (en) 2017-06-27
EP1605975A4 (en) 2006-04-19
EP3159357B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
BRPI0408085A (pt) composição e método para o tratamento e prevenção de infecções entéricas bacterianas
Peng et al. Pasteurella multocida: genotypes and genomics
Goodman et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins
Clemens et al. New-generation vaccines against cholera
BR0012974A (pt) Composição de vacina
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
BRPI0612656A8 (pt) composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica
BR0114785A (pt) Composição adjuvante, composição de vacina, e, métodos para desviar, a qualidade de uma resposta imunológica contra um antìgeno, para a manufatura de uma composição de vacina, e para tratar um indivìduo suscetìvel a ou sofrendo de uma doença.
WO1995014028A3 (en) Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
BR0210804A (pt) Vacinação de dose única com mycoplásma hyopneumoniae
BRPI0408094A (pt) processo para purificação de uma citolisina bacteriana, citolisina bacteriana, conjugado de polissacarìdeo capsular-pneumolisina bacteriano, composição imunogênica, vacina, processo de produção da vacina, método de tratamento ou prevenção de infecção por streptococcus pneumoniae, e, uso da pneumolisina ou do conjugado de polissacarìdeo-pneumolisina bacteriano
BR0010612A (pt) Vacinas
HRP20110320T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
BRPI0515516A (pt) composição imunogênica, vacina, métodos de fabricar uma vacina e de prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, método de preparar um globulina imune para uso na prevenção ou tratamento de infecção estafilocócica, composição farmacêutica, e, uso da composição farmacêutica
Cerquetti et al. Role of Clostridium difficile in childhood diarrhea
KR970703164A (ko) 헬리코박터류 감염의 치료 및 예방용 항원 제제(treatment and prevention of helicobacter infection)
BR0112919A (pt) Uso de óleos essenciais para combater infecção do trato gi por organismos semelhantes a helicobacter
CA2294701A1 (en) Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
FR21C1005I2 (fr) Antigenes de streptococcus pyogenes et fragments d'adn correspondants
SE9904581D0 (sv) A novel helicobacter pylori-binding substance and use thereof
BR0112497A (pt) Antìgenos de streptococcus pyogenes
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
CA2332686A1 (en) Novel 13 and 14-membered antibacterial and prokinetic macrolides and their intermediates

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: IMMURON LIMITED (AU)

B25G Requested change of headquarter approved

Owner name: IMMURON LIMITED (AU)

B12B Appeal against refusal [chapter 12.2 patent gazette]